Epidemiology of and Antibiotic Therapy for Helicobacter pylori Infection
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: 31 August 2026 | Viewed by 810
Special Issue Editor
Special Issue Information
Dear Colleagues,
The goal of Helicobacter pylori eradication is to completely eliminate the bacteria as part of the treatment or prevention of peptic ulcers, MALT lymphoma, atrophic gastritis, idiopathic iron deficiency anemia, and ITP, and it should also be considered in many cases of dyspepsia. The first choice today is usually a 10-14-day quadruple therapy with bismuth (PPI + bismuth + tetracycline + metronidazole). Where antibiotic resistance is low and there has been no previous use of macrolides, clarithromycin-based triple therapy (PPI + amoxicillin + clarithromycin) may be given, but it is becoming less popular due to its decreasing effectiveness. In case of failure, levofloxacin- or rifabutin-containing "salvage" treatment or personalized therapy based on resistance testing is recommended. The key to success is the right dose, sufficient duration, and good adherence; side effects (abdominal discomfort, diarrhea, taste disturbance) are common but can be mitigated by probiotics. To confirm cure, a ¹³C-urea breath test or stool antigen test is required 4 weeks after antibiotics and at least 2 weeks after PPI discontinuation. Reinfection is rare in adults. Acid reducers and bismuth should be avoided prior to diagnosis as they may cause false-negative results. In special situations (allergies, pregnancy, childhood), individual assessment and adherence to guidelines are necessary. Eradication reduces ulcer recurrence and the risk of gastric cancer in the long term.
Dr. Peter Birinyi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Helicobacter pylori infection
- bismuth citrate
- metronidazole
- tetracycline
- amoxicillin
- clarithromycin
- proton pump inhibitor
- amoxicillin
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
